Company Monitoring Page for AstraZeneca

latest headlines for company on cafepharma

AstraZeneca hauls kidney disease drug into the clinic after handing Ionis $30M in cash, $300M in milestones
Endpoints
Tue, 02/20/18 - 11:07 am
Tags:
AstraZeneca, kidney disease, Ionis Pharmaceuticals, AZD2373, antisense
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
Yahoo/Zacks.com
Mon, 02/19/18 - 11:42 am
Tags:
AstraZeneca, FDA, Imfinzi, non-small cell lung cancer
FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market
Endpoints
Sat, 02/17/18 - 10:44 am
Tags:
FDA, AstraZeneca, Imfinzi, lung cancer, Bavencio, Pfizer, Merck KGaA
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
Investors Business Daily
Sat, 02/3/18 - 09:09 am
Tags:
AstraZeneca, Lynparza, Tesaro, cancer, Rubraca, Clovis Oncology
AstraZeneca pins its hopes on China
Biopharma Dive
Fri, 02/2/18 - 10:54 pm
Tags:
China, AstraZeneca, earnings
AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints
Endpoints
Fri, 02/2/18 - 09:18 am
Tags:
AstraZeneca, PD-1 inhibitors, asthma, tralokinumab, lebrikizumab
AstraZeneca's 3-in-1 inhaler helps COPD patients in trial
Yahoo/Reuters
Fri, 01/26/18 - 09:37 am
Tags:
AstraZeneca, COPD, clinical trials, PT010
Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma
Endpoints
Sat, 01/20/18 - 02:56 pm
Tags:
AstraZeneca, Lynparza, Merck, ovarian cancer, asthma, Japan, Fasenra, EA Pharma, elobixibat
AstraZeneca gives itself top marks for R&D productivity makeover — but the jury is still out
Endpoints
Fri, 01/19/18 - 11:34 am
Tags:
R&D, AstraZeneca
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Endpoints
Fri, 01/12/18 - 10:39 am
Tags:
AstraZeneca, PARP inhibitors, FDA, Lynparza, metastatic breast cancer
2018 Healthcare And Biotech Outlook
Seeking Alpha
Sun, 01/7/18 - 12:41 pm
Tags:
AbbVie, Abbott Labs, Amgen, Allergan, AstraZeneca, Gilead Sciences, Bristol-Myers Squibb
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
Fri, 01/5/18 - 10:28 am
Tags:
China, Opdivo, Repatha, Lynparza, drug approvals, Bristol-Myers Squibb, Amgen, AstraZeneca, Eli Lilly, Gilead Sciences
AstraZeneca sells US rights to 4 non-core drugs
Biopharma Dive
Wed, 01/3/18 - 11:07 am
Tags:
AstraZeneca, ANI Pharmaceuticals, Atacand, Atacand HCT, Casodex, Arimidex
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Endpoints
Tue, 01/2/18 - 11:44 am
Tags:
Bristol-Myers Squibb, AstraZeneca, Opdivo, Lynparza, China
These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
Investors Business Daily
Tue, 01/2/18 - 11:42 am
Tags:
Europe, AstraZeneca, Lynparza, ovarian cancer, Novo Nordisk, diabetes, semaglutide
FDA Pulls Boxed Warnings on Asthma Risks on Some Inhalers
RAPS.org
Thu, 12/21/17 - 10:35 pm
Tags:
FDA, warnings, asthma, inhalers, ICS/LABA inhalers, GSK, Advair Diskus, AstraZeneca, Symbicort, Merck, Dulera
AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA
Yahoo/Zacks.com
Tue, 12/19/17 - 10:24 am
Tags:
AstraZeneca, Tagrisso, FDA, labeling, non-small cell lung cancer
Leif Johansson, AstraZeneca’s chairman, on possible Brexit aftermaths
GoinPharma
Thu, 12/14/17 - 09:23 pm
Tags:
AstraZeneca, Brexit, Leif Johansson
GlaxoSmithKline, now vying with AstraZeneca, scores brand-new market for Nucala
Fierce Pharma
Wed, 12/13/17 - 11:07 am
Tags:
GSK, AstraZeneca, Nucala, eosinophilic granulomatosis with polyangiitis
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
Endpoints
Fri, 12/8/17 - 11:46 am
Tags:
Pfizer, AstraZeneca, talazoparib, advanced breast cancer, Lynparza, PARP inhibitors

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.